Obesity Clinical Trial
— ObesiStressOfficial title:
Stress Management in Obesity During a Thermal Spa Residential Program: a Randomized Controlled Trial
Stress can lead to obesity via inappropriate eating. In addition, obesity is a major stress
factor. Furthermore, stressed people are also those who have the greatest difficulties to
lose weight. The relationships between obesity and stress are biological via the action of
stress on the major hormones regulating appetite (leptin, ghrelin). International
recommendation proposals suggest to implement stress management programs in obesity for a
sustainable weight loss. Moreover, stress and obesity are two public health issues. Among the
multiple physical and psychological consequences of stress and obesity, increased mortality
and cardiovascular morbidity seem the main concern. Many spa resorts are specialized in the
treatment of obesity in France but actually no thermal spa proposes a specific program to
manage stress in obesity.
The main hypothesis is that a thermal spa residential program (21 days) of stress management
in obesity will exhibit its efficacy through objective measures of well-being and
cardiovascular morbidity.
Status | Not yet recruiting |
Enrollment | 140 |
Est. completion date | April 1, 2021 |
Est. primary completion date | March 1, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Overweight or obese participants with Body Mass Index (BMI) >25 kg.m-2 - Spontaneously candidate to the spa program of Vichy for management of obesity - Aged over 18 years old - A stable weight during the last three months - No hepatic, renal or endocrine diseases uncontrolled - Ability to give a written informed consent -- Affiliated to French health care system (for France) Exclusion Criteria: - Participant refusal to participate - Pregnant and breastfeeding women |
Country | Name | City | State |
---|---|---|---|
France | CHU Clermont-Ferrand | Clermont-Ferrand |
Lead Sponsor | Collaborator |
---|---|
University Hospital, Clermont-Ferrand | Center of Auvergne for Obesity and its health-related risks (CALORIS), Auvergne, France, European Regional Development Fund, Hospital of Vichy, Boulevard Denière, 03200 Vichy, France, Innovatherm, LaPEC laboratory (EA 4278), Avignon University, Avignon, France, Regional Council of Auvergne-Rhône-Alpes, Spa resort of Vichy, Compagnie de Vichy, 1 et 3 avenue Eisenhower, 03200 Vichy, France, Université d'Auvergne |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | heart rate variability (biomarker of both stress and morbidity/mortality) | To assess the ability of a short spa residential program of management of work-related stress in increasing heart rate variability, a biomarker of both stress and morbidity/mortality. Heart rate variability will be measured by zephyr during 26h recording time |
HRV changes overtime is being assessed. Outcomes will be measured at inclusion, at the beginning of the spa program (day 0), day 21, at six months and at one year. | |
Secondary | skin conductance | skin conductance will be measured using Wirst band electrodes | Changes overtime is being assessed. Outcomes will be measured at inclusion, at the beginning of the spa program (day 0), day 21, at six months and at one year. | |
Secondary | blood flow velocity | blood flow velocity will be measured using laser speckle contrast imaging | Changes overtime is being assessed. Outcomes will be measured at inclusion, at the beginning of the spa program (day 0), day 21, at six months and at one year | |
Secondary | myocardial longitudinal strain | myocardial longitudinal strain will be measured using speckle tracking echocardiography | Changes overtime is being assessed. Outcomes will be measured at the beginning of the spa program (day 0) and at six months | |
Secondary | Genetic polymorphisms related to stress | Genetic polymorphisms related to stress will be measured using blood cells (angiotensin converting enzyme and serotonin) | Changes overtime is being assessed. Outcomes will be measured at inclusion, at the beginning of the spa program (day 0), day 21, at six months and at one year | |
Secondary | Demographics information | Demographics information will be obtained using a single questionnaire including questions on age, gender, qualification, personal work status, ethnicity, life and occupational events | Changes overtime is being assessed. Outcomes will be measured at inclusion, at the beginning of the spa program (day 0), day 21, at six months and at one year. | |
Secondary | Anthropometry | Anthropometry parameters will be obtained according to the ISAK recommendations | Changes overtime is being assessed. Outcomes will be measured at inclusion, at the beginning of the spa program (day 0), day 21, at six months and at one year | |
Secondary | Body composition | Body composition (muscle and fat) will be measured using Impedancemeter | Changes overtime is being assessed. Outcomes will be measured at inclusion, at the beginning of the spa program (day 0), day 21, at six months and at one year | |
Secondary | Body composition | Body composition (muscle and fat) will be measured using dual x-ray absorption | Changes overtime is being assessed. Outcomes will be measured at the beginning of the spa program (day 0) and at one year | |
Secondary | bone microarchitecture | bone microarchitecture will be measured using peripheral quantitative computed tomography | Changes overtime is being assessed. Outcomes will be measured at inclusion, at the beginning of the spa program (day 0), day 21, at six months and at one year. | |
Secondary | bone mass | bone mass will be measured using dual x-ray absorption | Changes overtime is being assessed. Outcomes will be measured at the beginning of the spa program (day 0) and at one year. | |
Secondary | bone mass | bone mass will be measured using quantitative ultrasounds | Changes overtime is being assessed. Outcomes will be measured at inclusion, at the beginning of the spa program (day 0), day 21, at six months and at one year. | |
Secondary | General Health | General Health will be measured using the General Health Questionnaire, (there is no score, just informative health information) | Changes overtime is being assessed. Outcomes will be measured at inclusion, at the beginning of the spa program (day 0), day 21, at six months and at one year. | |
Secondary | Physical Activity | Physical Activity will be measured using the Recent Physical Activity Questionnaire (All activities are categorised depending on intensity: sedentary (<1.5 MET); light (1.5 to <3 MET), moderate-to-vigorous (>3MET))Questionnaire | Changes overtime is being assessed. Outcomes will be measured at inclusion, at the beginning of the spa program (day 0), day 21, at six months and at one year. | |
Secondary | Depression and anxiety | Depression and anxiety will be measured using the Hospital anxiety and depression scale (scale range from 0 to 3, with a total score between 0 to 21. Threshold score is 8 | Changes overtime is being assessed. Outcomes will be measured at inclusion, at the beginning of the spa program (day 0), day 21, at six months and at one year | |
Secondary | Burn-out | Burn-out will be measured using the Maslach Burn Out Inventory (scale range from 0 to 6, with 0 = never and 6 = almost always) | Changes overtime is being assessed. Outcomes will be measured at inclusion, at the beginning of the spa program (day 0), day 21, at six months and at one year. | |
Secondary | Job content | Job content will be measured using the Karasek questionnaire (scale range from 1 to 4, with 1= not agreed and 4 = totally agreed) | Changes overtime is being assessed. Outcomes will be measured at inclusion, at the beginning of the spa program (day 0), day 21, at six months and at one year | |
Secondary | anxiety | anxiety will be measured using the state and trait anxiety inventory scale (scale range from 1 to 4, with a total score between 20 to 80. If <35 poor level of anxiety, if > 66 very high level of anxiety) | Changes overtime is being assessed. Outcomes will be measured at inclusion, at the beginning of the spa program (day 0), day 21, at six months and at one year | |
Secondary | mindfulness | mindfulness will be measured using the Freiburg mindfulness inventory scale (scale range from 1 to 4, with 1 = almost never, 4 = almost always) | Changes overtime is being assessed. Outcomes will be measured at inclusion, at the beginning of the spa program (day 0), day 21, at six months and at one year. | |
Secondary | self-efficacy | self-efficacy will be measured using the perceived self-efficacy scale (scale range from 1 to 4, with 1= wrong and 4 = true) | Changes overtime is being assessed. Outcomes will be measured at inclusion, at the beginning of the spa program (day 0), day 21, at six months and at one year | |
Secondary | Alexithymia | Alexithymia will be measured using the Toronto Alexithymia scale (scale range from 1 to 5, with 1 = not agreed, 5 = totally agreed) | Changes overtime is being assessed. Outcomes will be measured at inclusion, at the beginning of the spa program (day 0), day 21, at six months and at one year | |
Secondary | coping responses | coping responses will be measured using the brief COPE questionnaire (scale range from 1 to 4, with 1 = not agreed, 4 = totally agreed) | Changes overtime is being assessed. Outcomes will be measured at inclusion, at the beginning of the spa program (day 0), day 21, at six months and at one year | |
Secondary | emotion regulation | emotion regulation will be measured using the emotion regulation questionnaire (scale range from 1 to 7, with 1 = not agreed, 7 = totally agreed) | Changes overtime is being assessed. Outcomes will be measured at inclusion, at the beginning of the spa program (day 0), day 21, at six months and at one year. | |
Secondary | metacognition | metacognition will be measured using the metacognition questionnaire MQC-30 (scale range from 1 to 4, with 1 = not agreed, 4 = totally agreed) | Changes overtime is being assessed. Outcomes will be measured at inclusion, at the beginning of the spa program (day 0), day 21, at six months and at one year | |
Secondary | illness perception | illness perception will be measured using the brief illness perception questionnaire (B-IPQ 9 items, scale range from 0 to 10) | Changes overtime is being assessed. Outcomes will be measured at inclusion, at the beginning of the spa program (day 0), day 21, at six months and at one year | |
Secondary | lifestyle behaviours | lifestyle behaviours will be measured using the lifestyle questionnaire | Changes overtime is being assessed. Outcomes will be measured at inclusion, at the beginning of the spa program (day 0), day 21, at six months and at one year | |
Secondary | workplace stress | workplace stress will be measured using the Inner Correspondence/Peaceful Harmony with practices - ICPH (17 items, a 5-point scale from disagreement to agreement, scores >50% indicate higher agreement while scores <50 indicate disagreement). | : Changes overtime is being assessed. Outcomes will be measured at inclusion, at the beginning of the spa program (day 0), day 21, at six months and at one year. | |
Secondary | Basic biology | HbA1c (mmol/mol) will be measured using endocrine assays | Changes overtime is being assessed. Outcomes will be measured at inclusion, at the beginning of the spa program (day 0), day 21, at six months and at one year. | |
Secondary | appetite markers | Leptin (ng/mL) will be measured using endocrine assays | Changes overtime is being assessed. Outcomes will be measured at inclusion, at the beginning of the spa program (day 0), day 21, at six months and at one year. | |
Secondary | Pro-inflammatory cytokine | IL-1ß will be measured using endocrine assays | Changes overtime is being assessed. Outcomes will be measured at inclusion, at the beginning of the spa program (day 0), day 21, at six months and at one year | |
Secondary | Telomeres length | Telomeres length will be measured using endocrine assays | Changes overtime is being assessed. Outcomes will be measured at inclusion, at the beginning of the spa program (day 0), day 21, at six months and at one year | |
Secondary | stress markers | Cortisol (nmol/l) will be measured using endocrine assays | Changes overtime is being assessed. Outcomes will be measured at inclusion, at the beginning of the spa program (day 0), day 21, at six months and at one year. | |
Secondary | adrenal function | adrenal function will be measured using endocrine assays (Dehydroepiandrosterone - DHEAS) | Changes overtime is being assessed. Outcomes will be measured at inclusion, at the beginning of the spa program (day 0), day 21, at six months and at one year. | |
Secondary | neurotrophic factors | neurotrophic factors will be measured using endocrine assays (Brain-Derived Neurotrophic Factor -BDNF) | Changes overtime is being assessed. Outcomes will be measured at inclusion, at the beginning of the spa program (day 0), day 21, at six months and at one year. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04101669 -
EndoBarrier System Pivotal Trial(Rev E v2)
|
N/A | |
Recruiting |
NCT04243317 -
Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults
|
N/A | |
Terminated |
NCT03772886 -
Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball
|
N/A | |
Completed |
NCT03640442 -
Modified Ramped Position for Intubation of Obese Females.
|
N/A | |
Completed |
NCT04506996 -
Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2
|
N/A | |
Recruiting |
NCT06019832 -
Analysis of Stem and Non-Stem Tibial Component
|
N/A | |
Active, not recruiting |
NCT05891834 -
Study of INV-202 in Patients With Obesity and Metabolic Syndrome
|
Phase 2 | |
Active, not recruiting |
NCT05275959 -
Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI)
|
N/A | |
Recruiting |
NCT04575194 -
Study of the Cardiometabolic Effects of Obesity Pharmacotherapy
|
Phase 4 | |
Completed |
NCT04513769 -
Nutritious Eating With Soul at Rare Variety Cafe
|
N/A | |
Withdrawn |
NCT03042897 -
Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer
|
N/A | |
Completed |
NCT03644524 -
Heat Therapy and Cardiometabolic Health in Obese Women
|
N/A | |
Recruiting |
NCT05917873 -
Metabolic Effects of Four-week Lactate-ketone Ester Supplementation
|
N/A | |
Active, not recruiting |
NCT04353258 -
Research Intervention to Support Healthy Eating and Exercise
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Recruiting |
NCT03227575 -
Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control
|
N/A | |
Completed |
NCT01870947 -
Assisted Exercise in Obese Endometrial Cancer Patients
|
N/A | |
Recruiting |
NCT05972564 -
The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function
|
Phase 1/Phase 2 | |
Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
Recruiting |
NCT05371496 -
Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction
|
Phase 2 |